Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up

Published:2009-04-15 Issue:7 Volume:87 Page:1092-1095
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Clatworthy Menna R.,Friend Peter J.,Calne Roy Y.,Rebello Perpetua R.U.,Hale Geoffrey,Waldmann Herman,Watson Christopher J.E.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference24 articles.

1. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.;Xia;Biochem J,1993

2. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H.;Brett;Immunology,1996

3. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.;Issacs;Arthritis Rheum,2001

4. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?;Hale;Bone Marrow Transplant,2002

5. A review of Campath in autoimmune disease: Biologic therapy in the gray zone between immunosuppression and immunoablation.;Reiff;Hematology,2005

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection;Transplant International;2023-11-07

2. Immunosuppression Therapy in Kidney Transplantation;Urologic Clinics of North America;2022-05

3. Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient;Journal of Clinical Medicine;2021-08-18

4. Rejection Challenges: Diagnosis and Management;Challenges in Pediatric Kidney Transplantation;2021

5. Acute Rejection Following Kidney Transplantation: State-of-the-Art and Future Perspectives;Current Pharmaceutical Design;2020-08-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3